We protect your health through science

Investigation

Research Lines

Content with Investigacion Inmunidad Humoral y Vacunas frente al VIH .

Classical viral vaccines rely on the induction of neutralizing antibodies. In the case of infection by the human immunodeficiency virus (HIV), the viral spike has evolved to evade recognition by these antibodies. Despite these obstacles, certain monoclonal antibodies capable of neutralizing the majority of primary HIV-1 isolates have been successfully isolated and have demonstrated efficacy both in controlling viremia and in providing protection against infection in animal models. These are known as broadly neutralizing antibodies (bNAbs).


 

In order to identify the factors involved in the induction of these antibodies and to develop preventive strategies based on bNAb induction, we are pursuing the following research lines:

  1. Determination of factors associated with the induction of effective humoral responses in different scenarios: recent infection, chronic infection, co-infection with hepatitis C virus, reinfection, and pediatric infection, among others.
  2. Study of the effect of feminizing hormone therapy on the immune system of transgender women.
  3. Development of HIV-1 vaccine prototypes based on viral spike proteins incorporated into Virus-Like Particles (VLPs) from two sources:
    a) Selected from a library of randomly mutated spikes to enhance the accessibility of epitopes recognized by bNAbs.
    b) Derived from viruses present in individuals with broad neutralizing responses in recent infection.
  4. Isolation and characterization of new bNAbs against HIV-1 from individual B cells of individuals with an efficient neutralizing response. These antibodies could be used in both preventive and therapeutic strategies.
  5. Isolation of new monoclonal antibodies against other human pathogenic viruses, adapting the technology developed for HIV-1 antibody isolation, in collaboration with researchers from the National Center for Microbiology.
  6. Use of gene therapy vectors (Recombinant Adeno-Associated Viruses; rAAVs) to incorporate bNAbs and apply them in prophylactic and therapeutic strategies.

Research projects

Content with Investigacion Inmunidad Humoral y Vacunas frente al VIH .

Research Projects as Principal Investigators

Effect of Feminizing Hormone Therapy on the Immune Response in Transgender Women
Principal Investigator: Víctor Sánchez-Merino
Funding Agency: Intramural Health Strategic Action
Funding: €117,000
Participating Institutions: ISCIII, IRSICAIXA, 7 Infectious diseases units (Hospital General Universitario Gregorio Marañón (HGUGM-INF), Hospital Universitario La Paz (HULP), Hospital Universitario Infanta Leonor (HUIL), Hospital Fundación Jiménez Díaz (FJD), Fundación Universitario la Princesa (HUP), Hospital Universitario Ramón y Cajal (HURyC) y Hospital Universitario Doce de Octubre (HU12O), Centro Sandoval, 1 Gender Identity Unit, Facultad de psicología (UAM), Facultad de Geografía e Historia (UCM) and three ONGs
Duration: 01/01/2025- 31/12/2027
Project Reference: PI24CIII/00031

Design of Vaccine Prototypes based on HIV-1 Envelope presented on Virus-Like Particles and Nanodiscs
Principal Investigator: Eloísa Yuste Herranz
Funding agency: Knowledge Generation Projects. State Plan for Scientific and Technical Research and Innovation.
Funding: €125,000
Participating Institutions: ISCIII and University of UNSW (Sydney, Australia)
Duration: 01/09/24–31/12/28
Reference: Project PID2023-148729OB-100 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE.

 

Funding for Research Assistant Position. Project: New Approaches to Immunogen Design for the Induction of Anti-HIV-1 Broadly Neutralizing Antibodies (bNAbs) Based on Viral Envelope Proteins Presented on VLPs
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Youth Employment Plan (Community of Madrid)
Funding: Hiring of a senior graduate for 2 years
Participating Institutions: ISCIII
Duration: 01/04/2024 – 31/03/2026
Project Reference: SAL-GL-28125

Generation of an Adenovirus-Associated Vector for the Delivery of a Broadly Neutralizing Antibody (bNAb) Against HIV-1 That Does Not Induce Anti-Antibody Responses. Funding for Research Assistant Position. 
Principal Investigator: Víctor Sánchez Merino
Funding Agency: FUAX-Santander
Funding: €90,000
Participating Institutions: Universidad Alfonso X El Sabio and ISCIII
Duration: 01/04/2022 – 01/04/2025
Project Reference: 1.013.008

New Approaches to Immunogen Design for the Induction of Anti-HIV-1 Broadly Neutralizing Antibodies (bNAbs) Based on Viral Envelope Proteins Presented on Virus-Like Particles (VLPs). 
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Intramural Health Strategic Action
Funding: €77,000
Participating Institutions: Fraunhofer Institute (Germany) and ISCIII
Duration: 01/01/2021 – 30/06/2024
Project Reference: PI20CIII/00039

Development of Immunogens and Vaccination Strategies to Optimize the Induction of Broadly Neutralizing Antibodies (bNAbs) Against HIV-1.                                  
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Intramural Health Strategic Action
Funding: €117,000
Participating Institutions: Fraunhofer Institute (Germany) and ISCIII
Duration: 01/01/2018 – 31/12/2021
Personnel Hiring: One postdoctoral researcher for 3 years
Project Reference: PI17/00049

Isolation and Characterization of Broadly Neutralizing Antibodies Against HIV-1 from Recently Infected Patients.
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Health Strategic Action (ISCIII)
Funding: €57,475
Participating Institutions: IDIBAPS, Fraunhofer Institute (Germany), and ISCIII
Duration: 01/01/2014 – 30/04/2017
Project Reference: PI13/01528

Development of an HIV Vaccine: Isolation and Characterization of New Broadly Neutralizing Antibodies.
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Health Research Fund (ISCIII)
Funding: €116,765
Participating Institutions: IDIBAPS and ISCIII
Duration: 01/01/2010 – 31/12/2012
Project Reference: PI09/1459

Optimization of the HIV-1 Envelope Protein as an Immunogen.                            
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Spanish Foundation for AIDS Research and Prevention (FIPSE)
Funding: €141,845
Participating Institutions: IDIBAPS
Duration: 30/10/2008 – 31/08/2012
Personnel Hiring: One senior graduate for 3 years
Project Reference: 36780/08

Optimization of the HIV-1 Envelope Protein as an Immunogen.                           
Principal Investigator: Eloísa Yuste Herranz
Funding Agency: Ramón y Cajal Program (Ministry of Education and Science)
Funding: 5-year Ramón y Cajal Researcher contract + 3 years as I3
Participating Institutions: IDIBAPS
Duration: 2008 – 2016
Project Reference: RYC-2007-00788

R&D projects as part of the research team 

Determination of factors associated with protection against Human Immunodeficiency Virus type 1 Reinfection: Identification of protection correlates.
Principal Investigator: María Pernas Escario
Funding Agency: Gilead Sciences
Funding: €16,630
Participating Entities: Centro Sandoval and ISCIII
Duration: 01/01/2023 - 31/12/2023
Contract/Project File: GLD22/001144

EAVI2020: European AIDS Vaccine Initiative 2020
Principal Investigator: José Alcamí Pertejo
Funding Agency: Horizon 2020 (European Union; EU)
Funding: €403,829
Participating Entities: ISCIII and an EU consortium
Duration: 01/01/2015 - 30/04/2021
Contract/Project File: MPY1398/15

EHVA, European HIV Vaccine Alliance (EHVA): an EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates.
Principal Investigator: Felipe García Alcaide
Funding Agency: Horizon 2020 (European Union; EU)
Funding: €1,000,000
Participating Entities: IDIBAPS and an EU consortium
Duration: 01/01/2018 - 31/12/2020
Contract/Project File: 681032

Grup de Recerca VIH/SIDA
Principal Investigator: José María Gatell
Funding Agency: AGAUR_SGR14 (Generalitat de Catalunya-projects)
Funding: €63,000
Participating Entities: IDIBAPS
Duration: 01/01/2014 - 30/04/2017
Contract/Project File: 214_SGR_706

SIDA Vaccine Research Project (HIVACAT)
Principal Investigator: José María Gatell
Funding Agency: MINECO (INNPACTO Program)
Funding: €288,740
Participating Entities: IDIBAPS and Irsicaixa
Duration: 01/01/2013 - 31/03/2020
Contract/Project File: PT-2012-0325-010000

Design, synthesis, and anti-HIV-1 study of peptide domains of GB virus B
Principal Investigator: Isabel Haro
Funding Agency: Foundation for AIDS Research and Prevention (FIPSE)
Funding: €33,000
Participating Entities: IQAC-CSIC and IDIBAPS
Duration: 09/03/2010 - 30/11/2014
Contract/Project File: 36-0735-09
 

Publications

Sort
Category

FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.

13. Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, García-Álvarez M, Aldamiz-Echevarría T, Carrero A, Vázquez-Morón S, García-Broncano P, Diez C, Tejerina F, Guzmán-Fulgencio M, Resino S (*). FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. BMC Med. 2014, 12:198. (A; FI= 7.34; D1, Medicine, General & Internal; JCR 2014). PMID: 25367448. DOI: 10.1186/s12916-014-0198-y.

PUBMED

HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.

14. Guzmán-Fulgencio M, Berenguer J; Rallón N, Fernández-Rodríguez A, Miralles P, Soriano V, Jiménez-Sousa MA, Cosin J, Medrano J, García-Álvarez M, López JC, Benito JM, Resino S (*). HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. AIDS 2013; 27(8):1231-1238. (A; FI= 6.55; D1, Infectious Diseases; JCR 2013). PMID: 23811951. DOI: 10.1097/QAD.0b013e32835f5b9c.

PUBMED

Eva Orviz, Anabel Negredo, Oskar Ayerdi, Ana Vázquez, Ana Muñoz-Gomez, Sara Monzón, Petunia Clavo, Angel Zaballos, Mar Vera, Patricia Sánchez, Noemi Cabello, Pilar Jiménez, Jorge A Pérez-García, Sarai Varona, Jorge Del Romero, Isabel Cuesta, Alberto Delgado-Iribarren, Montse Torres, Iñigo Sagastagoitia, Gustavo Palacios, Vicente Estrada, Maria Paz Sánchez-Seco, Grupo Viruela del Simio Madrid CNM/ISCIII/HCSC/Sandoval.

Eva Orviz, Anabel Negredo, Oskar Ayerdi, Ana Vázquez, Ana Muñoz-Gomez, Sara Monzón, Petunia Clavo, Angel Zaballos, Mar Vera, Patricia Sánchez, Noemi Cabello, Pilar Jiménez, Jorge A Pérez-García, Sarai Varona, Jorge Del Romero, Isabel Cuesta, Alberto Delgado-Iribarren, Montse Torres, Iñigo Sagastagoitia, Gustavo Palacios, Vicente Estrada, Maria Paz Sánchez-Seco, Grupo Viruela del Simio Madrid CNM/ISCIII/HCSC/Sandoval. Monkeypox outbreak in Madrid (Spain): Clinical and virological aspects. J Infect. 2022 Jul 10;S0163-4453(22)00415-7. doi: 10.1016/j.jinf.2022.07.005.

DOI

European mitochondrial haplogroups are associated with CD4+ T-cell recovery in HIV-infected patients on combination antiretroviral therapy.

15. ​Guzmán-Fulgencio M; Berenguer J, Micheloud D, Fernández-Rodríguez A; García–Álvarez M, Jiménez-Sousa MA, Bellón JM, Campos Y, Cosin J, Aldámiz-Echevarría T, Catalán P, López JC, Resino S (*). European mitochondrial haplogroups are associated with CD4+ T-cell recovery in HIV-infected patients on combination antiretroviral therapy. J Antimicrob Chemoth 2013; 68 (10): 2349–2357 (A; FI= 5.44; D1, Infectious Diseases; JCR 2013). PMID: 23749950. DOI: 10.1093/jac/dkt206.

PUBMED

María Paz Sánchez-Seco, María José Sierra, Agustín Estrada-Peña, Félix Valcárcel, Ricardo Molina, Eva Ramírez de Arellano, Angeles Sonia Olmeda, Lucía García San Miguel, Maribel Jiménez, Luis J Romero, Anabel Negredo; Group for CCHFv Research. Widespread Detection of Multiple Strains of Crimean-Congo Hemorrhagic Fever Virus in Ticks, Spain.

María Paz Sánchez-Seco, María José Sierra, Agustín Estrada-Peña, Félix Valcárcel, Ricardo Molina, Eva Ramírez de Arellano, Angeles Sonia Olmeda, Lucía García San Miguel, Maribel Jiménez, Luis J Romero, Anabel Negredo; Group for CCHFv Research. Widespread Detection of Multiple Strains of Crimean-Congo Hemorrhagic Fever Virus in Ticks, Spain. Emerg Infect Dis. 2022 Feb;28(2):394-402. doi: 10.3201/eid2802.211308.

DOI

Negredo A, Sánchez-Ledesma M, Llorente F, Pérez-Olmeda M, Belhassen-García M, González-Calle D, Sánchez-Seco MP, Jiménez-Clavero MÁ. Retrospective Identification of Early Autochthonous Case of Crimean-Congo Hemorrhagic Fever, Spain, 2013

Negredo A, Sánchez-Ledesma M, Llorente F, Pérez-Olmeda M, Belhassen-García M, González-Calle D, Sánchez-Seco MP, Jiménez-Clavero MÁ. Retrospective Identification of Early Autochthonous Case of Crimean-Congo Hemorrhagic Fever, Spain, 2013. Emerg Infect Dis. 2021 Jun;27(6):1754-1756. doi: 10.3201/eid2706.204643.

DOI

Negredo A, Sánchez-Arroyo R, Díez-Fuertes F, de Ory F, Budiño MA, Vázquez A, Garcinuño Á, Hernández L, la Hoz González C, Gutiérrez-Arroyo A, Grande C, Sánchez-Seco P. Fatal Case of Crimean-Congo Hemorrhagic Fever Caused by Reassortant Virus, Spain, 2018.

Negredo A, Sánchez-Arroyo R, Díez-Fuertes F, de Ory F, Budiño MA, Vázquez A, Garcinuño Á, Hernández L, la Hoz González C, Gutiérrez-Arroyo A, Grande C, Sánchez-Seco P. Fatal Case of Crimean-Congo Hemorrhagic Fever Caused by Reassortant Virus, Spain, 2018. Emerg Infect Dis. 2021 Apr;27(4):1211-1215. doi: 10.3201/eid2704.203462.

DOI

Laura Davó, Laura Herrero, Maria Paz Sánchez-Seco, Nuria Labiod, David Roiz, Elena Gómez-Díaz, Lourdes Hernandez, Jordi Figuerola and Ana Vázquez. Real-time PCR assay to detect Granada virus and the related Massilia and Arrabida phleboviruses

Laura Davó, Laura Herrero, Maria Paz Sánchez-Seco, Nuria Labiod, David Roiz, Elena Gómez-Díaz, Lourdes Hernandez, Jordi Figuerola and Ana Vázquez. Real-time PCR assay to detect Granada virus and the related Massilia and Arrabida phleboviruses. Davó et al. Parasit Vectors. 2020 May 29;13(1):270. doi: 10.1186/s13071-020-04110-5.

DOI

María Velasco, María Paz Sánchez-Seco, Carolina Campelo, Fernando de Ory, Oriol Martin, Laura Herrero, Octavio J. Salmerón Béliz, Teodora Minguito, Mª Carmen Campos, Francisca Molero, Alejandro Algora and Ana Vázquez. Imported Human West Nile Virus Lineage 2 Infection in Spain

María Velasco, María Paz Sánchez-Seco, Carolina Campelo, Fernando de Ory, Oriol Martin, Laura Herrero, Octavio J. Salmerón Béliz, Teodora Minguito, Mª Carmen Campos, Francisca Molero, Alejandro Algora and Ana Vázquez. Imported Human West Nile Virus Lineage 2 Infection in Spain: Neurological and Gastrointestinal Complications. Viruses 2020 Jan 29;12(2):156. doi: 10.3390/v12020156.

DOI

Negredo A, Habela MÁ, Ramírez de Arellano E, Diez F, Lasala F, López P, Sarriá A, Labiod N, Calero-Bernal R, Arenas M, Tenorio A, Estrada-Peña A, Sánchez-Seco MP. Survey of Crimean-Congo Hemorrhagic Fever Enzootic Focus, Spain, 2011-2015

Negredo A, Habela MÁ, Ramírez de Arellano E, Diez F, Lasala F, López P, Sarriá A, Labiod N, Calero-Bernal R, Arenas M, Tenorio A, Estrada-Peña A, Sánchez-Seco MP. Survey of Crimean-Congo Hemorrhagic Fever Enzootic Focus, Spain, 2011-2015. Emerg Infect Dis. 2019 Jun;25(6):1177-1184. doi: 10.3201/eid2506.180877.

DOI

Ramírez de Arellano E, Sanchez-Lockhart M, Perteguer MJ, Bartlett M, Ortiz M, Campioli P, Hernández A, Gonzalez J, Garcia K, Ramos M, Jiménez-Clavero MÁ, Tenorio A, Sánchez-Seco MP, González F, Echevarría JE, Palacios G, Negredo A. First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain

Ramírez de Arellano E, Sanchez-Lockhart M, Perteguer MJ, Bartlett M, Ortiz M, Campioli P, Hernández A, Gonzalez J, Garcia K, Ramos M, Jiménez-Clavero MÁ, Tenorio A, Sánchez-Seco MP, González F, Echevarría JE, Palacios G, Negredo A. First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain. Viruses. 2019 Apr 19;11(4):360. doi: 10.3390/v11040360.

DOI

Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals.

3. Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Ardizone Jiménez B, Jiménez‑Sousa MA, Fernández-Rodríguez A, Martínez I (‡), Resino S (*‡). Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals. Aliment Pharmacol Ther 2022; 56 (8): 1224-1234 (A; FI= 9.52; D1, Pharmacology & Pharmacy; JCR 2021).

PUBMED DOI

Antibody levels to SARS-CoV-2 spike protein in mothers and children from delivery to six months later.

4. Martin-Vicente M, Carrasco I, Muñoz-Gomez MJ, Lobo AH, Mas V, Vigil-Vázquez S, Vázquez M, Manzanares A, Cano O, Alonso R, Sepúlveda-Crespo D, Tarancón-Díez L, Muñoz-Fernández MÁ, Muñoz-Chapuli M, Resino S#*, Navarro ML#, Martinez I#*. Antibody levels to SARS-CoV-2 spike protein in mothers and children from delivery to six months later. Birth. 2022 Jul 8:10.1111/birt.12667. doi: 10.1111/birt.12667. Online ahead of print. PMID: 35802776.

PUBMED

Hepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study.

5. Pérez-García F, Vázquez-Morón S, Burgueño-García I, José Muñoz-Gómez M, Zea-Sevilla MA, Calero M, Martínez I#, Rábano A#, Resino S#. Hepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study. J Infect Dis. 2022 Jun 27:jiac268. doi: 10.1093/infdis/jiac268. Online ahead of print. PMID: 35759220 (A; FI= 7.759; Q1 Microbiology; JCR 2021).

PUBMED

Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis.

6. Sepúlveda-Crespo D, Yélamos MB, Díez C, Gómez J, Hontañón V, Torresano-Felipe F, Berenguer J, González-García J, Ibañez-Samaniego L, Llop E, Olveira A, Martínez J, Resino S (‡ *), Martínez I (‡ *). Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis. Biomed Pharmacother 2022, 150: 113024. (A; FI= 7.42; D1, Pharmacology & Pharmacy; JCR 2021).

PUBMED DOI

. Environmental factors linked to hospital admissions in young children due to acute viral lower respiratory infections: A bidirectional case-crossover study.

7. Álvaro-Meca A, Goez MDC, Resino R, Matías V, Sepúlveda-Crespo D, Martínez I#, Resino S#. Environmental factors linked to hospital admissions in young children due to acute viral lower respiratory infections: A bidirectional case-crossover study. Environ Res. 2022 Sep; 212(Pt B):113319. doi: 10.1016/j.envres.2022.113319. PMID: 35447151. (A; FI= 8.431; D1 Public, Environmental & Occupational Health; JCR 2021).

PUBMED

Misdiagnosis rate of among negative COVID-19 patients in real-life with Panbio COVID-19 Antigen Rapid Test during 2021.

8. Ryan P, Pérez-García F, Torres-Macho J, Bibiano C, Ignacio Lazo J, Castaño-Ochoa G, Vidal-Alcántara EJ, Muñoz-Gómez MJ, Martínez I#, Resino S#. Misdiagnosis rate of among negative COVID-19 patients in real-life with Panbio COVID-19 Antigen Rapid Test during 2021. J Infect. 2022 May; 84(5):e42-e44. doi: 10.1016/j.jinf.2022.03.013. PMID: 35306106 (L; FI= 38.637; D1 Infectious Diseases; JCR 2021).

PUBMED

Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19.

11. Martín-Vicente M, Berenguer J, Muñoz-Gómez MJ, Díez C, Micán R, Pérez-Elías MJ, García-Fraile LJ, Peraire J, Suárez-García I, Jiménez-Sousa MÁ, Fernández-Rodríguez A, Vázquez M, Ryan P, González-García J, Jarrín I, Mas V, Martínez I#, Resino S#. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.002. PMID: 34752819 (L; FI= 38.637; D1 Infectious Diseases; JCR 2021).

PUBMED

Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients.

12. Martin-Vicente M#, Almansa R#, Martínez I#, Tedim AP, Bustamante E, Tamayo L, Aldecoa C, Gómez JM, Renedo G, Berezo JÁ, Cedeño JA, Mamolar N, García Olivares P, Herrán-Monge R, Cicuendez R, Enríquez P, Ortega A, Jorge N, Doncel C, de la Fuente A, Bustamante-Munguira J, Muñoz-Gómez MJ, González-Rivera M, Puertas C, Más V, Vázquez M, Pérez-García F, Rico-Feijoo J, Martín S, Motos A, Fernandez-Barat L, Eiros JM, Dominguez-Gil M, Ferrer R, Barbé F, Trapiello W, Kelvin DJ, Bermejo-Martin JF, Resino S, Torres A. Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. J Intern Med. 2022 Feb; 291(2):232-240. doi: 10.1111/joim.13386. PMID: 34611927 (A; FI= 13.068; D1 Medicine, General & Internal; JCR 2021).

PUBMED

Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

13. Sepulveda-Crespo D, Resino S*, Martinez I*. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs. 2021 Drugs. 2021 Mar; 81(4):419-443. doi: 10.1007/s40265-020-01458-x. PMID: 33400242. (R; FI= 11.431; D1 Pharmacology & Pharmacy; JCR 2021).

PUBMED

List of staff

Additional Information

Participation in research networks

Network Biomedical Research Center in Infectious Diseases
Participation: Member of the research team (Víctor Sánchez Merino); Coordinator of the "Preventive Vaccines against HIV-1" working group, HIV Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 2023 - Present
Code: CIBERINFEC, group CB21/13/00015

AIDS Research Network
Participation: Member of the research team (Víctor Sánchez Merino); Head of the bNAbs Detection and Characterization Working Group, Vaccine Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 01/01/2017-12/31/2021
Code: RETICS; RD16CIII/0002/0001

AIDS Research Network
Participation: Member of the research team (Víctor Sánchez Merino); Head of the Vaccine Development Working Group, Immunopathogenesis Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 01/01/2013-12/31/2017
Code: RETICS; RD12/0017

AIDS Research Network
Participation: Members of the research team (Víctor Sánchez Merino and Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 04/04/2008-12/31/2013
Code: RETICS; RD12/0017

Supervised doctoral theses

Development of immunogens and vaccination strategies to optimize the induction of broad-spectrum neutralizing antibodies against HIV-1. Student: Carolina Beltrán Pávez. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / ISCIII / Universitat de Barcelona. Defense date: 11/26/2018. Grade obtained: Excellent Cum Laude

Characterization of the neutralizing response of patients with recent HIV-1 infection and isolation of antibodies. Student: Amanda Fabra García. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / Universitat de Barcelona. Defense date: 07/20/2017. Grade obtained: Excellent Cum Laude

Broadly neutralizing antibody responses against HIV-1: Characterization and design of new immunogens. Student: Carolina Barbosa Ferreira. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / Universitat de Barcelona. Defense date: 02/25/2013. Qualification obtained: Excellent Cum Laude (European Doctorate)

Participation in research networks

Network Biomedical Research Center in Infectious Diseases
Participation: Member of the research team (Víctor Sánchez Merino); Coordinator of the "Preventive Vaccines against HIV-1" working group, HIV Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 2023 - Present
Code: CIBERINFEC, group CB21/13/00015

AIDS Research Network
Participation: Member of the research team (Víctor Sánchez Merino); Head of the bNAbs Detection and Characterization Working Group, Vaccine Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 01/01/2017-12/31/2021
Code: RETICS; RD16CIII/0002/0001

AIDS Research Network
Participation: Member of the research team (Víctor Sánchez Merino); Head of the Vaccine Development Working Group, Immunopathogenesis Program (Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 01/01/2013-12/31/2017
Code: RETICS; RD12/0017

AIDS Research Network
Participation: Members of the research team (Víctor Sánchez Merino and Eloísa Yuste Herranz)
Funding agency: ISCIII
Duration: 04/04/2008-12/31/2013
Code: RETICS; RD12/0017

Supervised doctoral theses

Development of immunogens and vaccination strategies to optimize the induction of broad-spectrum neutralizing antibodies against HIV-1. Student: Carolina Beltrán Pávez. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / ISCIII / Universitat de Barcelona. Defense date: 11/26/2018. Grade obtained: Excellent Cum Laude

Characterization of the neutralizing response of patients with recent HIV-1 infection and isolation of antibodies. Student: Amanda Fabra García. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / Universitat de Barcelona. Defense date: 07/20/2017. Grade obtained: Excellent Cum Laude

Broadly neutralizing antibody responses against HIV-1: Characterization and design of new immunogens. Student: Carolina Barbosa Ferreira. Thesis co-director: Víctor Sánchez Merino; Eloísa Yuste Herranz. Implementation entity: IDIBAPS / Universitat de Barcelona. Defense date: 02/25/2013. Qualification obtained: Excellent Cum Laude (European Doctorate)

The current director of CNM is Dr. José Miguel Rubio Muñoz.

Dr. José Miguel Rubio has a degree in Biological Sciences from the Universidad Autónoma de Madrid (1986) and a PhD in Biological Sciences from the same university (1992). He carried out his doctoral thesis at the Department of Genetics of the Universidad Autónoma de Madrid, as Associate Professor (1988-1989), and at the School of Biology of the University of East Anglia in Norwich, UK, as Senior Research Assistant (1989-1992).

During his postdoctoral period he obtained a grant from the European Commission within the Human Capital and Mobility Program to be carried out at the University of “La Sapienza” in Rome, Italy and the Institute of Molecular Biology and Biotechnology in Crete, Greece (1993-1994). Subsequently, he made a further stay funded by the WHO and the university itself at the Department of Entomology, Wageningen University, The Netherlands (1994-1996).

Since 1997 he has been a member of the Instituto de Salud Carlos III (ISCIII), where he joined the Department of Parasitology of the National Center of Microbiology, as an EU-INCO postdoctoral fellow and later with a grant from the Autonomous Community of Madrid (CAM). She was part of the founding group of the National Center for Tropical Medicine (2003-2006) and of the 24/7 Alerts and Emergencies Unit (2006-2018) and is currently Head of the Malaria and Emerging Parasitosis Unit of the National Microbiology Center and is part, as research staff, of the Center for Biomedical Research Network on Infectious Diseases (CIBERINFEC/ISCIII).

During his scientific career he has been Visiting Scientist at the Leonidas e Marie Dean Center (FIOCRUZ-AMAZONAS, Manaus, Brazil) and is an External Consultant of the Parasitology Departments of Cairo University (Egypt) and the Medical Research Center (MRC) of Kuala Lumpur (Malaysia).  He also belongs or has belonged to different national and international committees:  Member of the expert group for malaria control of the European Centre for Disease Control (ECDC) since 2011; Expert-Evaluator for health programs of the European Commission since 2004; Spanish Representative (commissioned by ISCIII and MSC) in the Technical Scientific Committee of the TDR (WHO) 2007-2008; Spanish Deputy Focal Point for microbiology at the European Centre for Disease Control (ECDC) from 2012 to 2020; and, member of the Research Ethics Committee of ISCIII until 2019.

In this period he has published more than 100 articles in international indexed journals, 10 book chapters and has been co-editor of two books in the area of malaria, tropical medicine and neglected diseases. He has participated in 58 competitively funded research projects, 20 of them international, having been the principal investigator in 8 national and 11 international projects as PI of the project or WP leader. In addition, he has led five agreements with companies. Currently he has been awarded four sexenios of research, being presented this year 2025 to the fifth. In the teaching field, he participates in different postgraduate programs in the areas of microbiology and parasitology, having directed seven doctoral theses and more than 20 Master's or Degree final projects, both nationally and internationally. ​​​​​

El laboratorio de Referencia e Investigación en Resistencia a Antibióticos ofrece una amplia cartera de servicios al Sistema Nacional de Salud, las cuales pueden solicitarse en cnm-laboratorios.isciii.es. Jefe del Laboratorio: Jesús Oteo Iglesias (Punto focal Nacional de Resistencia antibiótica).

Dispone de dos programas de Vigilancia oficiales y gratuitos que engloban los ensayos ofertados ya sea como aislamientos individuales o mediante estudio de brotes. El Laboratorio utiliza asimismo técnicas de PCR en tiempo real para la detección de genes de resistencia, estas técnicas se han adaptado a un formato multiplex que permite detectar varios genes en la misma reacción. En los últimos años se han incluido metodologías basadas en la secuenciación de genomas completos para el análisis de bacterias multiresistentes (WGS).

Programa de vigilancia de Haemophilus influenzae. Responsables: María Pérez Vázquez (Punto focal Nacional de Haemophilus influenzae) y Belén Aracil. Laboratorio encargado de la identificación, estudio de sensibilidad y análisis genotípico de aislados de Haemophilus influenzae, centrándose esencialmente en la patología invasiva debida este patógeno. 

Programa de vigilancia de Resistencia a Antibióticos. Responsables: María Pérez Vázquez  y Belén Aracil (Punto focal Nacional de Resistencia antibiótica). Laboratorio encargado de la identificación, el estudio de sensibilidad antibiótica, y el diagnóstico fenotípico y genotípico de los diferentes mecanismos de resistencia a antibióticos fundamentalmente en enterobacterias y gram-negativos no fermentadores y Enterococcus spp.

Estudio de brotes. Responsables: Belén Aracil y María Pérez Vázquez. El programa incluye la caracterización de brotes nosocomiales y clones emergentes de alto riesgo mediante diferentes técnicas moleculares (tabla resumen). Éstas, nos permiten realizar estudios filogenéticos con el fin de obtener una información detallada acerca la relación entre los diferentes aislados y su trazabilidad. El objetivo final es generar datos que se transfieren a los hospitales como ayuda para la prevención o control de la propagación del brote.

Acreditación y Calidad. Responsable: Belén Aracil. El laboratorio Referencia e Investigación en Resistencia a Antibióticos ha sido de los primeros en el ISCIII en la utilización de técnicas acreditadas por la Entidad Nacional de Acreditaciones (ENAC). Este laboratorio consiguió la primera acreditación homologada de técnicas diagnósticas en 2012, programa que ha sido ampliado, de manera que en la actualidad más de la mitad de las técnicas ofrecidas al Sistema Nacional de Salud están debidamente acreditadas por ENAC.

Técnicos responsables de las técnicas realizadas en el Laboratorio: Noelia Lara Fuella y Verónica Bautista Sánchez.

En la siguiente imagen se resumen las técnicas ofrecidas al Sistema Nacional de Salud.

PROGRAMAS NOMBRE CARTERA SERVICIO PATÓGENO DETERMINACIÓN, DETECCIÓN, ANÁLISIS MÉTODOS

Programa de vigilancia de Haemophilus

Programa de vigilancia de resistencia a antibióticos.

Identificación bacteriana

Haemophilus sp.

Enterobacterias, gram-negativos no fermentadores, Enterococcus spp

Identificación bacteriana

Bioquímicos

MALDI TOF

Secuenciación de RNAr

Identificación capsular

Haemophilus influenzae

 

Identificación capsular fenotípica y genotípica

Aglutinación serológica en latex

PCR ind/multiplex

Determinación de Sensibilidad

Haemophilus sp.

Enterobacterias, gram-negativos no fermentadores, Enterococcus

 

Determinación de Sensibilidad

Microdilución                

Tiras epsilon               

Kirby Bauer

Métodos fenotípicos de detección de mecanismos de resistencia

Enterobacterias, gram-negativos no fermentadores,

 

Métodos fenotípicos de detección de mecanismos de resistencia

Discos y tabletas combinados con inhibidores                

Tiras combinadas     

Test de Hodge modificado

CabaNP                               

Inmunocromatografía CBP

Métodos genotípicos de detección de mecanismos de resistencia

Haemophilus sp.

Enterobacterias, gram-negativos no fermentadores, Enterococcus

 

ADN, PCR y secuenciación

PCR ind/multiplex

Análisis comparativo de las secuencias

Tipificación molecular/análisis filogenéticos

Haemophilus sp.

Enterobacterias, gram-negativos no fermentadores, Enterococcus

 

Corte enzimas de restricción, electroforesis

ADN, PCR y secuenciación

Preparación de librerías y secuenciación y análisis de genomas completos

 

PFGE

 

MLST

 

WGS